Rxsight vs Glaukos: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Rxsight Inc (RXST)

Q3 20266 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

July 20266 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

Latest6 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

Glaukos Corp (GKOS)

Q3 202630 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

September 202630 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

Latest30 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.